EC
RGLS

EcoR1 Capital’s Regulus Therapeutics RGLS Stock Holding History

EcoR1 Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-188,681
Closed -$870K – 63
2020
Q1 		$870K Buy
+188,681
New +$1.65M 0.09% 46
2019
Q4 		– Sell
-104,909
Closed -$755K – 52
2019
Q3 		$755K Sell
104,909
-6,202
-6% -$50.5K 0.1% 37
2019
Q2 		$1.39M Buy
+111,111
New +$1.28M 0.14% 37
2017
Q4 		– Sell
-43,660
Closed -$6.55M – 40
2017
Q3 		$6.55M Buy
43,660
+12,750
+41% +$1.6M 0.87% 23
2017
Q2 		$3.66M Buy
30,910
+18,327
+146% +$3.06M 0.65% 23
2017
Q1 		$2.49M Buy
+12,583
New +$2.39M 0.63% 19

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

EcoR1 Capital's RGLS Position: Q2 2020 in Review

EcoR1 Capital sold out of Regulus Therapeutics (RGLS) in Q2 2020, closing a stake of 188,681 shares — an estimated $870K sold.

EcoR1 Capital first reported a position in RGLS in Q1 2017 and held it in 6 quarters. The position peaked at $6.55M in Q3 2017. 34 funds tracked by Wall St. Rank hold RGLS as of Q2 2020.

  • EcoR1 Capital reported no remaining Regulus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • EcoR1 Capital sold 188,681 Regulus Therapeutics shares in Q2 2020, an estimated $870K.
  • EcoR1 Capital first reported a position in Regulus Therapeutics in Q1 2017 and held it in 6 quarters.
  • EcoR1 Capital's Regulus Therapeutics position peaked at $6.55M in Q3 2017.
  • 34 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.